Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
If Viking Therapeutics Is Acquired, Here’s Who Wins
08:50am, Tuesday, 26'th May 2026
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with a
Prediction: These 2 Obesity Drug Stocks Could Double in 2026
04:04am, Tuesday, 26'th May 2026
These players are seeing exciting results in clinical trials.
Don't Buy Viking Therapeutics Stock Until You Read This
08:00pm, Monday, 25'th May 2026
Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increas
Is Viking Therapeutics a Top Takeover Target?
04:31pm, Saturday, 23'rd May 2026
Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
12:36pm, Thursday, 21'st May 2026
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Could Viking Therapeutics Be the Next Eli Lilly?
08:10am, Thursday, 21'st May 2026
Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.
Viking Therapeutics to Participate at Upcoming Investor Conferences
07:05am, Thursday, 21'st May 2026
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Best Weight Loss Drug Stocks to Buy in 2026
11:15pm, Wednesday, 20'th May 2026
Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
08:45pm, Monday, 18'th May 2026
There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.
Three Biotechs That Are Top Takeover Targets
01:55pm, Monday, 18'th May 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
12:52pm, Wednesday, 13'th May 2026
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a m
Viking Therapeutics: Market Betting On Big Upside Through 2030
12:00pm, Tuesday, 05'th May 2026
Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging glob
